Northern Trust Corp Purchases 11,304 Shares of Immatics (NASDAQ:IMTX)

Northern Trust Corp grew its position in shares of Immatics (NASDAQ:IMTX) by 31.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 47,226 shares of the company’s stock after buying an additional 11,304 shares during the quarter. Northern Trust Corp’s holdings in Immatics were worth $336,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Virtus ETF Advisers LLC lifted its holdings in shares of Immatics by 34.8% during the 4th quarter. Virtus ETF Advisers LLC now owns 9,594 shares of the company’s stock valued at $68,000 after buying an additional 2,479 shares during the period. T. Rowe Price Investment Management Inc. lifted its holdings in shares of Immatics by 43.7% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 10,604,777 shares of the company’s stock valued at $75,400,000 after buying an additional 3,225,141 shares during the period. Marshall Wace LLP bought a new position in shares of Immatics during the 4th quarter valued at $409,000. Wasatch Advisors LP lifted its holdings in shares of Immatics by 9.7% during the 4th quarter. Wasatch Advisors LP now owns 957,052 shares of the company’s stock valued at $6,805,000 after buying an additional 84,541 shares during the period. Finally, Guggenheim Capital LLC bought a new position in shares of Immatics during the 4th quarter valued at $101,000. 64.41% of the stock is owned by institutional investors.

Immatics Stock Performance

Shares of Immatics stock opened at $5.57 on Monday. Immatics has a one year low of $3.30 and a one year high of $13.77. The stock’s fifty day moving average is $4.54 and its 200 day moving average is $5.55. The stock has a market cap of $677.03 million, a P/E ratio of -8.44 and a beta of 0.87.

Immatics (NASDAQ:IMTX) last announced its earnings results on Tuesday, May 13th. The company reported ($0.35) EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.04. Immatics had a negative return on equity of 15.90% and a negative net margin of 47.94%. The company had revenue of $20.12 million for the quarter, compared to analysts’ expectations of $14.92 million. Analysts predict that Immatics will post -0.72 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. Deutsche Bank Aktiengesellschaft assumed coverage on Immatics in a report on Wednesday, May 28th. They set a “buy” rating and a $10.00 price target on the stock. Wall Street Zen cut Immatics from a “hold” rating to a “strong sell” rating in a report on Thursday, May 22nd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Immatics in a report on Tuesday, April 1st. One investment analyst has rated the stock with a sell rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Immatics presently has an average rating of “Moderate Buy” and a consensus price target of $14.67.

Immatics Company Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.